scholarly journals Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast Cancer

2018 ◽  
Author(s):  
Fatma Sen
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Systemic Treatment ◽  
Adjuvant Systemic Treatment ◽  
Hormone Receptor Positive

scholarly journals Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor–Positive Early Breast Cancer: Lights and Shadows

2019 ◽  
Vol 37 (11) ◽  
pp. 862-866 ◽  
Author(s):  
Meredith M. Regan ◽  
Gini F. Fleming ◽  
Barbara Walley ◽  
Prudence A. Francis ◽  
Olivia Pagani
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Systemic Treatment ◽  
Premenopausal Women ◽  
Adjuvant Systemic Treatment ◽  
Hormone Receptor Positive

scholarly journals Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

2019 ◽  
Author(s):  
Chris Twelves ◽  
Sue Cheeseman ◽  
Will Sopwith ◽  
Matthew Thompson ◽  
Majid Riaz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Hormone Receptor ◽  
Systemic Treatment ◽  
Metastatic Breast ◽  
Visceral Metastasis ◽  
Hormone Receptor Positive ◽  
Epidermal Growth

Abstract BACKGROUND Study aimed to characterise treatment and outcomes for patients with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC) within a large regional cancer centre, as a benchmark for evaluating real-world impact of novel therapies.METHODS Retrospective longitudinal cohort, using electronic patient records of adult females with a first diagnosis of HR+/HER2- MBC January 2012 - March 2018.RESULTS 196 women were identified with HR+/HER2- MBC. Median age was 67 years, 85.2% were post-menopausal and median time between primary diagnosis and metastasis was 5.4 years. Most (75.1%) patients received endocrine therapy as first line systemic treatment (1st LoT); use of 1st LoT chemotherapy halved between 2012 and 2017. Patients receiving 1st LoT chemotherapy were younger and more likely to have visceral metastasis (p<0.01). Median OS was 29.5 months and significantly greater for patients with exclusively non-visceral metastasis (p<0.01). The adjusted hazard ratio for death of patients with visceral (or CNS) metastasis was 1.91 relative to those with exclusively non-visceral metastasis.CONCLUSIONS Diverse endocrine therapies predominate as 1st LoT for patients with HR+/HER2- MBC, chemotherapy being associated with more aggressive disease in younger patients, emphasising the importance of using effective and tolerable therapies early.

scholarly journals Endocrine Therapy Versus Chemotherapy as First Line Treatment in Metastatic Hormone Receptor Positive Breast Cancer

2021 ◽  
Vol 107 (1_suppl) ◽  
pp. 5-5
Author(s):  
E. Aboelkheir* ◽  
A. Ashour ◽  
S. Fadel ◽  
W. Arafat
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Hormone Receptor ◽  
Systemic Treatment ◽  
Metastatic Breast ◽  
Mtor Inhibitors ◽  
Line Treatment ◽  
First Line ◽  
Hormone Receptor Positive ◽  
First Line Treatment

Introduction: The standard treatment of hormone receptor positive Her2 negative metastatic breast cancer is endocrine therapy with or without targeted therapy (e.g.CDK4/6inhibitors and mTOR inhibitors). Chemotherapy is indicated only in visceral crisis and the presence of visceral metastases is not indication for chemotherapy Aim of study The retrospective study aimed to characterize treatment and outcomes for patients with hormone receptor positive metastatic breast cancer in Alexandria clinical oncology department to review change in treatment trend during the last 10 years. Physician questionnaire to determine their preferences in choosing treatment. Methods Retrospective study using patient files of adult female diagnosed and treated at Clinical Oncology and Nuclear Medicine Department, Alexandria Main University Hospitals during the period from January 2010 to December 2019. Physician questionnaire was done by physician recruitment via online survey & scientific meetings. Results: The study identified 611 women with hormone receptor positive metastatic breast cancer, median age was 50years, 48.9% were postmenopausal, 56.7% of hormone receptor positive, Her2 negative patients received chemotherapy as first line systemic treatment, 69.5% of these patients received chemotherapy as first line treatment in the first 5years. But, 48.8% of these patients received chemotherapy as first line in the last 5years and the study showed that median overall survival for all studied patients was 34 months. In contrast, the physician questionnaire showed that 75% of physicians prefer endocrinal therapy as first line treatment for hormone receptor positive, Her2 negative metastatic breast cancer. Conclusion: There is significant change in practice pattern in choosing the first line treatment between the first and last 5 years. Also, there is a discrepancy between practice pattern and physician preferences in choosing the first line systemic treatment for hormone receptor positive, Her2 negative metastatic breast cancer. The reason is the unavailability of most targeted agents (e.g; CDK4/6 inhibitors and mTOR inhibitors) and some hormonal agents such as fulvestrant.

Use of Oncotype DX in systemic treatment decision making for patients with stage I and II, hormone receptor positive, HER2/neu-negative breast cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e11515-e11515
Author(s):  
Xiaofu Zhu ◽  
Susan Faye Dent ◽  
Lise Paquet ◽  
Tinghua Zhang ◽  
Nadine A. Graham ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Hormone Receptor ◽  
Systemic Treatment ◽  
Treatment Decision ◽  
Oncotype Dx ◽  
Stage I ◽  
Treatment Decision Making ◽  
Hormone Receptor Positive

scholarly journals Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

2019 ◽  
Author(s):  
Chris Twelves ◽  
Sue Cheeseman ◽  
Will Sopwith ◽  
Matthew Thompson ◽  
Majid Riaz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Hormone Receptor ◽  
Systemic Treatment ◽  
Metastatic Breast ◽  
Visceral Metastasis ◽  
Hormone Receptor Positive ◽  
Epidermal Growth

Abstract BACKGROUND Study aimed to characterise treatment and outcomes for patients with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC) within a large regional cancer centre, as a benchmark for evaluating real-world impact of novel therapies such as CDK4/6 inhibitors.METHODS Retrospective longitudinal cohort, using electronic patient records of adult females with a first diagnosis of HR+/HER2- MBC January 2012 - March 2018.RESULTS 196 women were identified with HR+/HER2- MBC. Median age was 67 years, 85.2% were post-menopausal and median time between primary diagnosis and metastasis was 5.4 years. Most (75.1%) patients received endocrine therapy as first line systemic treatment (1st LoT); use of 1st LoT chemotherapy halved between 2012 and 2017. Patients receiving 1st LoT chemotherapy were younger and more likely to have visceral metastasis ( p <0.01). Median OS was 29.5 months and significantly greater for patients with exclusively non-visceral metastasis ( p <0.01). The adjusted hazard ratio for death of patients with visceral (or CNS) metastasis was 1.91 relative to those with exclusively non-visceral metastasis.CONCLUSIONS Diverse endocrine therapies predominate as 1st LoT for patients with HR+/HER2- MBC, chemotherapy being associated with more aggressive disease in younger patients, emphasising the importance of using effective and tolerable therapies early.

Sign in / Sign up

Export Citation Format

Share Document